Retail Comparable Store Prescriptions Increased 0.9 Percent – Comparable Store Non-COVID Acute Prescriptions Increased 11.9 Percent
Revenues of $6.01 billion, Compared to Prior Year Revenues of $6.16 billion
Net Loss per Share of $2.03, Compared to Prior Year Net Loss per Share of $0.24
Adjusted Net Loss per Share of $0.60, Compared to Prior Year Adjusted Net Income per Share of $0.38, Driven by Non-Cash Impairment Charges and Cycling Prior Year COVID Vaccination Benefit
Adjusted EBITDA of $100.1 million, Compared to the Prior Year Adjusted EBITDA of $138.9 million
Increases Fiscal 2023 Revenue and Maintains Fiscal 2023 Adjusted EBITDA Guidance

Rite Aid Corporation (NYSE:RAD) today reported operating results for its first fiscal quarter ended May 28, 2022.

"We continue to make strides on our journey to transform Rite Aid and define the modern pharmacy. In the first quarter we increased our non-COVID prescriptions, reduced SG&A, built momentum at Elixir and delivered solid results across the business. The entire Rite Aid team looks forward to advancing our pharmacists' role in improving health outcomes," said Heyward Donigan, president and CEO.

Consolidated First Quarter Summary

(dollars in thousands)	Thirteen Week Period Ended
		May 28, 2022		May 29, 2021
Revenues	$	6,014,583	$	6,160,985
Net loss		(110,191)		(13,057)
Adjusted EBITDA		100,130		138,877

For the first quarter the company reported a net loss of $110.2 million, or $2.03 loss per share, Adjusted Net Loss of $32.8 million, or $0.60 loss per share, and Adjusted EBITDA of $100.1 million, or 1.7 percent of revenues.

Revenues for the quarter were $6.01 billion compared to revenues of $6.16 billion in the prior year's quarter.

First quarter net loss was $110.2 million, or $2.03 per share, compared to last year's first quarter net loss of $13.1 million, or $0.24 per share. First quarter adjusted net loss was $32.8 million, or $0.60 per share, compared to last year's first quarter adjusted net income of $20.9 million or $0.38 per share. The increase in adjusted net loss is due primarily to higher facility exit and impairment charges driven by the Company's previously announced store closure decisions and a decrease in Adjusted EBITDA. These items were partially offset by an increase in gain on sale of assets resulting from script file sales of certain of the store closures.

Retail Pharmacy Segment

(dollars in thousands)	Thirteen Week Period Ended
		May 28, 2022		May 29, 2021
Revenues	$	4,345,356	$	4,351,682
Adjusted EBITDA		73,682		94,914

Retail Pharmacy Segment revenues decreased 0.1 percent over the prior year quarter, driven by a reduction in COVID vaccine and testing revenue as well as store closures, offset by an increase in non-COVID prescriptions. Same store sales for the first quarter increased 4.6 percent over the prior year period, consisting of a 6.6 percent increase in pharmacy sales, partially offset by a 0.5 percent decrease in front-end sales. Front-end same store sales, excluding cigarettes and tobacco products, were flat. The number of prescriptions filled in same stores, adjusted to 30-day equivalents, increased 0.9 percent over the prior year period. Total non-COVID same store prescriptions increased 3.7 percent, with same store maintenance prescriptions increasing 1.4 percent and other same store acute prescriptions increasing 11.9 percent. Prescription sales accounted for 70.8 percent of total drugstore sales. Total store count at the end of the first quarter was 2,361.

Retail Pharmacy Segment Adjusted EBITDA was $73.7 million, or 1.7 percent of revenues, for the first quarter compared to last year's first quarter Adjusted EBITDA of $94.9 million, or 2.2 percent of revenues. The decline in Adjusted EBITDA was due to decreased gross profit, partially offset by a decrease in Adjusted EBITDA selling, general and administrative (SG&A) expenses of $40.5 million. Gross profit was negatively impacted by the decline in COVID-19 vaccinations and testing. The gross profit headwind from reduced COVID related services was partially offset by an increase in prescriptions filled and improved front end gross margin. SG&A expenses benefited from lower payroll, occupancy and other operating costs due to store closures and cost control initiatives.

Pharmacy Services Segment

(dollars in thousands)	Thirteen Week Period Ended
		May 28, 2022		May 29, 2021
Revenues	$	1,725,857	$	1,872,282
Adjusted EBITDA		26,448		43,963

Pharmacy Services Segment revenues were $1.7 billion for the quarter, a decrease of 7.8 percent compared to the prior year quarter. The decrease in revenues was primarily the result of a planned decrease in Elixir Insurance membership and a previously announced client loss due to industry consolidation, offset by higher retained rebates from our new rebate aggregation arrangement and increased utilization of higher cost drugs.

Pharmacy Services Segment Adjusted EBITDA was $26.4 million, or 1.5 percent of revenues, for the first quarter compared to last year's first quarter Adjusted EBITDA of $44.0 million, or 2.4 percent of revenues. The reduction in Adjusted EBITDA resulted from the decline in revenues associated with lost clients, as discussed above, and an increase in the medical loss ratio at Elixir insurance, partially offset by higher retained rebates from our new rebate aggregation arrangement.

Outlook for Fiscal 2023

The Company has increased its outlook for Fiscal 2023 revenues, due to increased utilization of higher cost drugs at Elixir and is maintaining its guidance for Adjusted EBITDA.

Total revenues are expected to be between $23.6 billion and $24.0 billion in fiscal 2023. Retail Pharmacy Segment revenue is expected to be between $17.35 billion and $17.65 billion and Pharmacy Services Segment revenue is expected to be between $6.25 billion and $6.35 billion (net of any intercompany revenues to the Retail Pharmacy Segment).

Net loss is expected to be between $246.3 million and $203.3 million. Our estimates for net loss have increased due to increased impairment charges for closed stores and an increase in interest expense due to recent and anticipated interest rate increases throughout the year.

Adjusted EBITDA is expected to be between $460 million and $500 million. Retail Pharmacy Segment Adjusted EBITDA is expected to be between $320 million and $350 million and Pharmacy Services Segment Adjusted EBITDA is expected to be between $140 million and $150 million.

Adjusted net loss per share is expected to be between $(1.19) and $(0.66).

Capital expenditures are expected to be approximately $250 million, with a focus on investments in digital capabilities, technology, prescription file purchases, distribution center automation and store remodels.

We expect to generate positive free cash flow in Fiscal 2023.

Conference Call Broadcast

Rite Aid will hold an analyst call at 8:30 a.m. Eastern Time today with remarks by Rite Aid's management team. The call will be broadcast via the Internet at https://investors.riteaid.com. The telephone replay will be available beginning at 12:00 p.m. Eastern Time on June 23, 2022 and ending at 11:59 p.m. Eastern Time on July 24, 2022. To access the replay of the call, telephone (800) 770-2030 or (647) 362-9199 and enter the seven-digit reservation number 9029129. The webcast replay of the call will also be available at https://investors.riteaid.com starting at 12 p.m. Eastern Time today. The playback will be available until the company's next conference call.

About Rite Aid Corporation

Rite Aid Corporation is on the front lines of delivering healthcare services and retail products to Americans 365 days a year. Our pharmacists are uniquely positioned to engage with customers and improve their health outcomes. We provide an array of whole being health products and services for the entire family through over 2,300 retail pharmacy locations across 17 states. Through Elixir, we provide pharmacy benefits and services to millions of members nationwide. For more information, visit www.riteaid.com.

Cautionary Statement Regarding Forward-Looking Statements

Statements in this release that are not historical, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding Rite Aid's outlook and guidance for fiscal 2023; the continued impact of the global coronavirus (COVID-19) pandemic on Rite Aid's business; Rite Aid's store closure program; and any assumptions underlying any of the foregoing. Words such as "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "predict," "project," "should," and "will" and variations of such words and similar expressions are intended to identify such forward-looking statements.

These forward-looking statements are not guarantees of future performance and involve risks, assumptions and uncertainties, including, but not limited to: risks related to the prolonged impact of the COVID-19 global pandemic and the emerging new variants, including the government responses thereto; the impact of COVID-19 on our workforce, operations, stores, expenses, and supply chain, and the operations or behaviors of our customers, suppliers and business partners; our ability to successfully implement our store closure program and other strategies; the impact of our high level of indebtedness, the ability to refinance such indebtedness on acceptable terms and our ability to satisfy our obligations and the other covenants contained in our debt agreements; outcome of pending or new litigation, including related to Opioids, "usual and customary" pricing or other matters; our ability to monetize the CMS receivable created in our Part D business; general competitive, economic, industry, market, political (including healthcare reform) and regulatory conditions (including changes to laws or regulations relating to labor or wages), as well as other factors that impact the markets in which we operate; the impact of private and public third-party payers continued reduction in prescription drug reimbursements and efforts to encourage mail order; our ability to manage expenses and our investments in working capital; our ability to achieve the benefits of our efforts to reduce the costs of our generic and other drugs; our ability to achieve cost savings and other benefits of our restructuring efforts within our anticipated timeframe, if at all; the outcome of our continuing efforts to monitor and comply with applicable laws, regulations, policies and procedures; and our ability to partner and have relationships with health plans and health systems.

These and other risks, assumptions and uncertainties are more fully described in Item 1A (Risk Factors) of our most recent Annual Report on Form 10-K and in other documents that we file or furnish with the Securities and Exchange Commission (the "SEC"), which you are encouraged to read. To the extent that COVID-19 adversely affects our business and financial results, it may also have the effect of heightening many of such risk factors.

Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by such forward-looking statements. Accordingly, you are cautioned not to rely on these forward-looking statements, which speak only as of the date they are made.

The degree to which COVID-19 may adversely affect Rite Aid's results and operations, including its ability to achieve its outlook for fiscal 2023 guidance, will depend on numerous evolving factors and future developments, which are highly uncertain, including, but not limited to, federal, state and local governmental policies and initiatives designed to reduce the transmission of COVID-19 and emerging new variants and how quickly and to what extent normal economic and operating conditions can resume. As a result, the impact on Rite Aid's financial and operating results cannot be reasonably estimated with specificity at this time, but the impact could be material. Rite Aid expressly disclaims any current intention, and assumes no duty, to update publicly any forward-looking statement after the distribution of this release, whether as a result of new information, future events, changes in assumptions or otherwise.

All references to "Company" and "Rite Aid" as used throughout this release refer to Rite Aid Corporation and its affiliates.

Reconciliation of Non-GAAP Financial Measures

Rite Aid separately reports financial results on the basis of Adjusted Net Income (Loss), Adjusted Net Income (Loss) per Diluted Share, Adjusted EBITDA, Adjusted EBITDA Gross Profit and Adjusted EBITDA SG&A, which are non-GAAP financial measures. See the attached tables for a reconciliation of Adjusted Net Income (Loss), Adjusted Net Income (Loss) per Diluted Share and Adjusted EBITDA to net income (loss), and net income (loss) per diluted share, which are the most directly comparable GAAP financial measures. Adjusted Net Income (Loss) and Adjusted Net Income (Loss) per Diluted Share exclude amortization expense, merger and acquisition-related costs, non-recurring litigation and other contractual settlements, gains or losses on debt modifications and retirements, LIFO adjustments, goodwill and intangible asset impairment charges, restructuring-related costs, the gain or loss on Bartell acquisition, and the change in estimate related to manufacturer rebate receivables. Rite Aid believes Adjusted Net Income (Loss) and Adjusted Net Income (Loss) per Diluted Share serve as appropriate measures to be used in evaluating the performance of its business and help its investors better compare its operating performance over multiple periods.

Adjusted EBITDA is defined as net income (loss) excluding the impact of income taxes, interest expense, depreciation and amortization, LIFO adjustments, charges or credits for facility exit and impairment, goodwill and intangible asset impairment charges, inventory write-downs related to store closings, gains or losses on debt modifications and retirements, and other items (including stock-based compensation expense, merger and acquisition-related costs, non-recurring litigation and other contractual settlements, severance, restructuring-related costs, costs related to facility closures, gain or loss on sale of assets, the gain or loss on Bartell acquisition, and the change in estimate related to manufacturer rebate receivables). The add back of LIFO (credit) charge when calculating Adjusted EBITDA, Adjusted Net Income (Loss) and Adjusted Net Income (Loss) per Diluted Share removes the entire impact of LIFO (credits) charges, and effectively reflects Rite Aid's results as if the company was on a FIFO inventory basis. Rite Aid believes Adjusted EBITDA serves as an appropriate measure in evaluating the performance of its business and helps its investors better compare its operating performance with its competitors.

Adjusted EBITDA Gross Profit includes LIFO adjustments, depreciation and amortization (COGS portion only) and other items. See the attached tables for a reconciliation of Adjusted EBITDA Gross Profit to Revenue, which is the most directly comparable GAAP financial measure. Adjusted EBITDA SG&A excludes depreciation and amortization (SG&A portion only), stock-based compensation expense, merger and acquisition-related costs, non-recurring litigation and other contractual settlements, and other items. See the attached tables for a reconciliation of Adjusted EBITDA SG&A to Revenue, which is the most directly comparable GAAP financial measure. The Company believes Adjusted EBITDA Gross Profit and Adjusted EBITDA SG&A serve as appropriate measures in evaluating the performance of its business and helps its investors better compare its operating performance with its competitors.

RITE AID CORPORATION AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS
(Dollars in thousands)
(unaudited)



			May 28, 2022			February 26, 2022
ASSETS
Current assets:
	Cash and cash equivalents		$	56,060		$	39,721
	Accounts receivable, net			1,449,745			1,343,496
	Inventories, net of LIFO reserve of $487,173 and $487,173			1,974,759			1,959,389
	Prepaid expenses and other current assets			88,860			106,749
		Total current assets		3,569,424			3,449,355
Property, plant and equipment, net				985,121			989,167
Operating lease right-of-use assets				2,723,405			2,813,535
Goodwill				879,136			879,136
Other intangibles, net				282,950			291,196
Deferred tax assets				20,071			20,071
Other assets				89,666			86,543
		Total assets	$	8,549,773		$	8,529,003

LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
	Current maturities of long-term debt and lease financing obligations		$	5,016		$	5,544
	Accounts payable			1,461,238			1,571,261
	Accrued salaries, wages and other current liabilities			787,591			780,632
	Current portion of operating lease liabilities			574,392			575,651
		Total current liabilities		2,828,237			2,933,088
Long-term debt, less current maturities				3,026,456			2,732,986
Long-term operating lease liabilities				2,526,607			2,597,090
Lease financing obligations, less current maturities				14,392			14,830
Other noncurrent liabilities				162,457			151,976
		Total liabilities		8,558,149			8,429,970

Commitments and contingencies				-			-
Stockholders' equity:
	Common stock			55,623			55,752
	Additional paid-in capital			5,913,210			5,910,299
	Accumulated deficit			(5,961,772	)		(5,851,581	)
	Accumulated other comprehensive loss			(15,437	)		(15,437	)
		Total stockholders' equity		(8,376	)		99,033
		Total liabilities and stockholders' equity	$	8,549,773		$	8,529,003

RITE AID CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS
(Dollars in thousands, except per share amounts)
(unaudited)



		Thirteen weeks ended May 28, 2022			Thirteen weeks ended May 29, 2021
Revenues		$	6,014,583		$	6,160,985
Costs and expenses:
	Cost of revenues		4,817,854			4,876,110
	Selling, general and administrative expenses		1,217,929			1,245,362
	Facility exit and impairment charges		66,571			8,831
	Interest expense		48,119			49,121
	Loss on debt retirements, net		-			396
	Gain on sale of assets, net		(29,196	)		(6,558	)

			6,121,277			6,173,262

Loss before income taxes			(106,694	)		(12,277	)
Income tax expense			3,497			780
	Net loss	$	(110,191	)	$	(13,057	)



Basic and diluted loss per share:

Numerator for loss per share:
	Net loss attributable to common stockholders - basic and diluted	$	(110,191	)	$	(13,057	)



Denominator:
	Basic and diluted weighted average shares		54,348			53,852


	Basic and diluted loss per share	$	(2.03	)	$	(0.24	)


RITE AID CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS
(Dollars in thousands)
(unaudited)



				Thirteen weeks ended May 28, 2022			Thirteen weeks ended May 29, 2021


OPERATING ACTIVITIES:
Net loss				$	(110,191	)	$	(13,057	)
Adjustments to reconcile to net cash (used in) provided by operating activities:
	Depreciation and amortization				70,073			75,859
	Facility exit and impairment charges				66,571			8,831
	LIFO credit				-			(3,993	)
	Change in allowances for uncollectible accounts receivable				3,763			-
	Gain on sale of assets, net				(29,196	)		(6,558	)
	Stock-based compensation expense				3,334			2,811
	Loss on debt retirements, net				-			396
	Changes in operating assets and liabilities:
		Accounts receivable			(104,458	)		(149,487	)
		Inventories			(15,827	)		11,918
		Accounts payable			(137,572	)		50,527
		Operating lease right-of-use assets and operating lease liabilities			(14,812	)		(5,909	)
		Other assets			751			7,978
		Other liabilities			15,327			34,559
			Net cash (used in) provided by operating activities		(252,237	)		13,875
INVESTING ACTIVITIES:
	Payments for property, plant and equipment				(73,176	)		(59,164	)
	Intangible assets acquired				(12,248	)		(5,436	)
	Proceeds from dispositions of assets and investments				30,839			2,448
	Proceeds from sale-leaseback transactions				-			7,456
			Net cash used in investing activities		(54,585	)		(54,696	)
FINANCING ACTIVITIES:
	Net proceeds from revolver				291,000			39,000
	Principal payments on long-term debt				(977	)		(91,941	)
	Change in zero balance cash accounts				33,691			51,957
	Financing fees paid for early debt redemption				-			(2	)
	Payments for taxes related to net share settlement of equity awards				(553	)		(35	)
	Deferred financing costs paid				-			(580	)
			Net cash provided by (used in) financing activities		323,161			(1,601	)
Increase (decrease) in cash and cash equivalents					16,339			(42,422	)
Cash and cash equivalents, beginning of period					39,721			160,902
Cash and cash equivalents, end of period				$	56,060		$	118,480


RITE AID CORPORATION AND SUBSIDIARIES

SUPPLEMENTAL SEGMENT OPERATING INFORMATION
(Dollars in thousands)
(unaudited)


		Thirteen weeks ended May 28, 2022			Thirteen weeks ended May 29, 2021

Retail Pharmacy Segment
	Revenues (a)	$	4,345,356		$	4,351,682
	Cost of revenues (a)		3,247,999			3,181,748
	Gross profit		1,097,357			1,169,934
	LIFO credit		-			(3,993	)
	FIFO gross profit		1,097,357			1,165,941
	Adjusted EBITDA gross profit		1,106,652			1,168,338

	Gross profit as a percentage of revenues		25.25	%		26.88	%
	LIFO credit as a percentage of revenues		0.00	%		-0.09	%
	FIFO gross profit as a percentage of revenues		25.25	%		26.79	%
	Adjusted EBITDA gross profit as a percentage of revenues		25.47	%		26.85	%

	Selling, general and administrative expenses		1,117,214			1,156,039
	Adjusted EBITDA selling, general and administrative expenses		1,032,970			1,073,424
	Selling, general and administrative expenses as a percentage of revenues		25.71	%		26.57	%
	Adjusted EBITDA selling, general and administrative expenses as a percentage of revenues		23.77	%		24.67	%

	Cash interest expense		45,244			46,024
	Non-cash interest expense		2,875			3,097
	Total interest expense		48,119			49,121

	Adjusted EBITDA		73,682			94,914
	Adjusted EBITDA as a percentage of revenues		1.70	%		2.18	%


Pharmacy Services Segment
	Revenues (a)	$	1,725,857		$	1,872,282
	Cost of revenues (a)		1,626,485			1,757,341
	Gross profit		99,372			114,941

	Gross profit as a percentage of revenues		5.76	%		6.14	%

	Adjusted EBITDA		26,448			43,963
	Adjusted EBITDA as a percentage of revenues		1.53	%		2.35	%

(a) -

Revenues and cost of revenues include $56,630 and $62,979 of inter-segment activity for the thirteen weeks ended May 28, 2022 and May 29, 2021, respectively, that is eliminated in consolidation.

RITE AID CORPORATION AND SUBSIDIARIES
SUPPLEMENTAL INFORMATION
RECONCILIATION OF NET LOSS TO ADJUSTED EBITDA
(In thousands)
(unaudited)



				Thirteen weeks ended May 28, 2022			Thirteen weeks ended May 29, 2021


Reconciliation of net loss to adjusted EBITDA:
	Net loss			$	(110,191	)	$	(13,057	)
	Adjustments:
		Interest expense			48,119			49,121
		Income tax expense			3,497			780
		Depreciation and amortization			70,073			75,859
		LIFO credit			-			(3,993	)
		Facility exit and impairment charges			66,571			8,831
		Loss on debt retirements, net			-			396
		Merger and Acquisition-related costs			-			3,886
		Stock-based compensation expense			3,334			2,811
		Restructuring-related costs			22,646			5,932
		Inventory write-downs related to store closings			7,955			472
		Litigation and other contractual settlements			18,271			14,000
		Gain on sale of assets, net			(29,196	)		(6,558	)
		Other			(949	)		397
			Adjusted EBITDA	$	100,130		$	138,877
			Percent of revenues		1.66	%		2.25	%


RITE AID CORPORATION AND SUBSIDIARIES
SUPPLEMENTAL INFORMATION
ADJUSTED NET (LOSS) INCOME
(Dollars in thousands, except per share amounts)
(unaudited)


				Thirteen weeks ended May 28, 2022			Thirteen weeks ended May 29, 2021

Net loss				$	(110,191	)	$	(13,057	)
	Add back - Income tax expense				3,497			780
			Loss before income taxes		(106,694	)		(12,277	)

	Adjustments:
		Amortization expense			20,626			20,460
		LIFO credit			-			(3,993	)
		Loss on debt retirements, net			-			396
		Merger and Acquisition-related costs			-			3,886
		Restructuring-related costs			22,646			5,932
		Litigation and other contractual settlements			18,271			14,000

			Adjusted (loss) income before income taxes		(45,151	)		28,404

			Adjusted income tax (benefit) expense (a)		(12,322	)		7,470
			Adjusted net (loss) income	$	(32,829	)	$	20,934

	Adjusted net (loss) income per diluted share:

	Numerator for adjusted net (loss) income per diluted share:
		Adjusted net (loss) income		$	(32,829	)	$	20,934



	Denominator:
		Basic weighted average shares			54,348			53,852
		Outstanding options and restricted shares, net			-			971
		Diluted weighted average shares			54,348			54,823

			Net loss per diluted share	$	(2.03	)	$	(0.24	)

			Adjusted net (loss) income per diluted share	$	(0.60	)	$	0.38

(a)	The fiscal year 2023 and 2022 annual effective tax rates, calculated using a federal rate plus a net state rate that excluded the impact of state NOL's, state credits and valuation allowance, was used for the thirteen weeks ended May 28, 2022 and May 29, 2021, respectively.

RITE AID CORPORATION AND SUBSIDIARIES
SUPPLEMENTAL INFORMATION
RECONCILIATION OF ADJUSTED EBITDA GROSS PROFIT AND RECONCILIATION OF ADJUSTED EBITDA SELLING,
GENERAL AND ADMINISTRATIVE EXPENSES- RETAIL PHARMACY SEGMENT
(In thousands)
(unaudited)



					Thirteen weeks ended May 28, 2022			Thirteen weeks ended May 29, 2021


Reconciliation of adjusted EBITDA gross profit:
	Revenues				$	4,345,356		$	4,351,682
	Gross Profit					1,097,357			1,169,934
	Addback:
		LIFO credit				-			(3,993	)
		Depreciation and amortization (cost of goods sold portion only)				2,893			2,097
		Other				6,402			300
			Adjusted EBITDA gross profit		$	1,106,652		$	1,168,338
			Percent of revenues			25.47	%		26.85	%



Reconciliation of adjusted EBITDA selling, general and administrative expenses:
	Revenues				$	4,345,356		$	4,351,682
	Selling, general and administrative expenses					1,117,214			1,156,039
	Less:
		Depreciation and amortization (SG&A portion only)				53,215			59,768
		Stock-based compensation expense				3,102			2,771
		Merger and Acquisition-related costs				-			3,886
		Restructuring-related costs				17,371			1,621
		Litigation and other contractual settlements				9,952			14,000
		Other				604			569
			Adjusted EBITDA selling, general and administrative
				expenses	$	1,032,970		$	1,073,424
			Percent of revenues			23.77	%		24.67	%



				Adjusted EBITDA	$	73,682		$	94,914


RITE AID CORPORATION AND SUBSIDIARIES
SUPPLEMENTAL INFORMATION
RECONCILIATION OF NET LOSS GUIDANCE TO ADJUSTED EBITDA GUIDANCE
YEAR ENDING MARCH 4, 2023
(In thousands)
(unaudited)


				Guidance Range
				Low			High

Total Revenues				$	23,600,000		$	24,000,000

Pharmacy Services Segment Revenues				$	6,250,000		$	6,350,000

Gross Capital Expenditures				$	250,000		$	250,000


Reconciliation of net loss to adjusted EBITDA:
	Net loss			$	(246,300	)	$	(203,300	)
	Adjustments:
		Interest expense			210,000			210,000
		Income tax benefit			(15,000	)		(18,000	)
		Depreciation and amortization			290,000			290,000
		LIFO charge			15,000			15,000
		Facility exit and impairment charges			130,000			130,000
		Restructuring-related costs			60,000			60,000
		Litigation and other contractual settlements			18,300			18,300
		Gain on sale of assets, net			(35,000	)		(35,000	)
		Other			33,000			33,000
			Adjusted EBITDA	$	460,000		$	500,000


RITE AID CORPORATION AND SUBSIDIARIES
SUPPLEMENTAL INFORMATION
RECONCILIATION OF NET LOSS GUIDANCE TO ADJUSTED NET LOSS GUIDANCE
YEAR ENDING MARCH 4, 2023
(In thousands)
(unaudited)



				Guidance Range
				Low			High

Net loss				$	(246,300	)	$	(203,300	)
	Add back - income tax benefit				(15,000	)		(18,000	)
			Loss before income taxes		(261,300	)		(221,300	)

	Adjustments:
		Amortization expense			79,000			79,000
		LIFO charge			15,000			15,000
		Restructuring-related costs			60,000			60,000
		Litigation and other contractual settlements			18,300			18,300

			Adjusted loss before adjusted income taxes		(89,000	)		(49,000	)

			Adjusted income tax benefit		(24,000	)		(13,000	)
			Adjusted net loss	$	(65,000	)	$	(36,000	)


			Diluted adjusted net loss per share	$	(1.19	)	$	(0.66	)

View source version on businesswire.com: https://www.businesswire.com/news/home/20220623005204/en/

Rite Aid Corporation Reports Fiscal 2023 First Quarter Results